Inactivated Mouse Urokinase


SKU: MUPA-IN Categories: ,

Product Description

Inactivated Mouse Urokinase

Inactivated two-chain HMW mouse urokinase, recombinantly produced in insect cells. Prepared from active mouse uPA by active site-specific inactivation with Phe-Pro-Arg chloromethyl ketone followed by removal of excess inhibitor by extensive dialysis.

Gene ID: 18792
Swiss-Prot/UniProt ID: P06869

View sample datasheet
View sample certificate of analysis
View material safety data sheet
Ask a question about this product

Additional Information



Molecular Weight

Extinction Coefficient



Shipping Conditions




Sample Size

Sample Concentration

Sample Volume

Gene Name

Gene ID

UniProt ID

1. Merchan JR, Tang J, Hu G et-al. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J. Natl. Cancer Inst. 2006;98 (11): 756-64. doi:10.1093/jnci/djj208Pubmed citation

2. Suelves M, Vidal B, Serrano AL et-al. uPA deficiency exacerbates muscular dystrophy in MDX mice. J. Cell Biol. 2007;178 (6): 1039-51. doi:10.1083/jcb.200705127Free text at pubmedPubmed citation

3. Bryer SC, Fantuzzi G, Van rooijen N et-al. Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. J. Immunol. 2008;180 (2): 1179-88. J. Immunol. (link)Pubmed citation

4. Ilkovitch D, Handel-fernandez ME, Herbert LM et-al. Antitumor effects of Mucin 1/sec involves the modulation of urokinase-type plasminogen activator and signal transducer and activator of transcription 1 expression in tumor cells. Cancer Res. 2008;68 (7): 2427-35. doi:10.1158/0008-5472.CAN-07-5651Pubmed citation

5. Van den broeck T, Stevenaert F, Taveirne S et-al. Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator. Blood. 2008;112 (13): 5046-51. doi:10.1182/blood-2008-06-164350Pubmed citation

6. Jo M, Takimoto S, Montel V et-al. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice. Am. J. Pathol. 2009;175 (1): 190-200. doi:10.2353/ajpath.2009.081053Free text at pubmedPubmed citation

8. Sisson TH, Nguyen MH, Yu B et-al. Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration. Blood. 2009;114 (24): 5052-61. doi:10.1182/blood-2008-12-196212Free text at pubmedPubmed citation

9. Botkjaer KA, Deryugina EI, Dupont DM et-al. Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism. Mol. Cancer Res. 2012;10 (12): 1532-43. doi:10.1158/1541-7786.MCR-12-0349Free text at pubmedPubmed citation

10. Ilkovitch D, Carrio R, Lopez DM. uPA and uPA-receptor are involved in cancer-associated myeloid-derived suppressor cell accumulation. Anticancer Res. 2012;32 (10): 4263-70. Anticancer Res. (link)Pubmed citation

11. Sanderson-smith ML, Zhang Y, Ly D et-al. A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection. PLoS Pathog. 2013;9 (7): e1003469. doi:10.1371/journal.ppat.1003469Free text at pubmedPubmed citation

12. Wu F, Catano M, Echeverry R, et al. Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke. J Neurosci. 2014;34(43):14219-32. Link to article

13. Endo-munoz L, Cai N, Cumming A, et al. Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis. PLoS ONE. 2015;10(8):e0133592. Link to article.